Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer
Lists
Only you see this
Abstract
NIRST holds promise as a potential clinical tool that can be seamlessly integrated into existing clinical workflow within the infusion suite. By providing early assessment of RCB, NIRST has potential to improve breast cancer patient management strategies.
BibTeX
@inproceedings{cao2023near,
author = {Xu Cao and Kristen E. Muller and Mary D. Chamberlin and Jiang Gui and Peter A. Kaufman and Gary N. Schwartz and Roberta M. diFlorio‐Alexander and Brian W. Pogue and Keith D. Paulsen and Shudong Jiang},
title = {{Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer}},
booktitle = {Clinical},
year = {2023},
doi = {10.1158/1078-0432.ccr-23-1593},
}Loading related content...